We plan to create an immunocytokine complex where one of the bispecificantibody parts binds to IFNβ and neutralizes its effect, and the secondshould be able to bind to the ErbB2 receptor on the tumor cell surface.IFNβ is supposed to locally accumulate at the tumor and metastasis sites,which excludes the adverse systemic reactions underlying the clinical pictureof the side effects typical of IFNβ monotherapy. Here, IFNB1 is linked to neoplasm.